Import trade restrictions for 3002590000 80
This table contains information on trade restrictions for the import of goods into the EU and the EU into third countries. The table contains information on trade restrictions which are imposed due to customs unions, preferences, tariff quotas, customs unions, veterinary controls, third country duties and non-preferential tariff quotas.
| Origin country | Start | Duty / Tax | Legal base Measure type | |
|---|---|---|---|---|
1011 | ERGA OMNES 1011 | 01-01-2002 | 0 % | Third country duty 103 |
 FO | Faroe Islands FO | 01-01-1997 | 0 % | Tariff preference 142 |
XL | Melilla XL | 01-01-1999 | 0 % | Accession act0001/85 Tariff preference 142 |
 SM | San Marino SM | 01-01-2006 | 0 % | Customs union duty 106 |
 TR | Türkiye TR | 01-01-2006 | 0 % | Customs union duty 106 |
 AD | Andorra AD | 01-01-2006 | 0 % | Customs union duty 106 |
 1007 | EU-Switzerland agreement: re-imported goods 1007 | 01-01-2007 | 0 % | Tariff preference 142 |
 GB | United Kingdom GB | 01-01-2021 | 0 % | Tariff preference 142 |
2080 | OCTs (Overseas Countries and Territories) 2080 | 01-01-2021 | 0 % | Tariff preference 142 |
 TN | Tunisia TN | 01-03-1998 | 0 % | Tariff preference 142 |
 MA | Morocco MA | 01-03-2000 | 0 % | Tariff preference 142 |
 LB | Lebanon LB | 01-04-2006 | 0 % | Tariff preference 142 |
 JO | Jordan JO | 01-05-2002 | 0 % | Tariff preference 142 |
XC | Ceuta XC | 01-07-1991 | 0 % | Accession act0001/85 Tariff preference 142 |
 US | United States US | 01-07-2026 | 0 % | Tariff preference 142 |
 SY | Syria SY | 01-08-1994 | 0 % | Tariff preference 142 |
 DZ | Algeria DZ | 01-09-2005 | 0 % | Tariff preference 142 |
1011 | ERGA OMNES 1011 | 01-11-2026 | 2 EUR | Union handling fee 800 |
1011 | ERGA OMNES 1011 | 01-11-2026 | 3 EUR | Low-value consignment customs duty 107 |
2000 | Preferential origin in accordance with the Agreement in the form of an Exchange of Letters between the European Union and the Kingdom of Morocco on the amendment of Protocols 1 and 4 to the Euro-Mediterranean Agreement establishing an association between the European Communities and their Member States, of the one part, and the Kingdom of Morocco, of the other part. 2000 | 03-10-2025 | 0 % | Tariff preference 142 |
 IL | Israel IL | 16-05-2023 | 0 % | Tariff preference 142 |
| CH | Switzerland CH | 25-10-2000 | 0 % | Tariff preference 142 |
| Origin country | Start | Duty / Tax | Legal base Measure type | |
|---|---|---|---|---|
 IR | Iran, Islamic Republic of IR | 01-01-2022 | Document required banned without it | Import control on restricted goods and technologies 711 |
 GL | Greenland GL | 01-08-2024 | Document required banned without it | Veterinary control 410 |
| FO | Faroe Islands FO | 01-08-2024 | Document required banned without it | Veterinary control 410 |
1008 | All third countries 1008 | 01-08-2024 | Document required banned without it | Veterinary control 410 |
 EU | European Union EU | 14-11-2023 | Document required banned without it | Veterinary control 410 |
1011 | ERGA OMNES 1011 | 20-05-2023 | Document required banned without it | Import control - CITES 710 |
 RU | Russian Federation RU | 20-07-2025 | Document required banned without it | Import/export restriction - Common Military List (CML) goods 738 |
 BY | Belarus BY | 20-07-2025 | Document required banned without it | Import control 731 |
1011 | ERGA OMNES 1011 | 10-02-2023 | Document required banned without it | Import control on REACH 761 |
 UA | Ukraine UA | 24-06-2026 | Document required banned without it | Import control 762 |
| UA | Ukraine UA | 24-06-2026 | Document required banned without it | Import control 760 |
Explanation of trade restrictions
Erga Omnes means "for all".
Third countries are countries that are not part of the EU.
GSP means "Generalised System of Preferences".
GSP Plus means "Generalised System of Preferences Plus".
European Economic Area (EEA) means all EU member states and Iceland, Liechtenstein and Norway.
OCTs stands for "Overseas Countries and Territories". They are countries and territories that are not part of the EU. More information
CARIFORUM is a regional economic integration organisation comprising 15 Caribbean Community (CARICOM) countries and the Dominican Republic.
SADC EPA stands for "Southern African Development Community - Economic Partnership Agreement".
Duty means "customs duties".
Estimate the import cost for 300259
- Customs value €1,000.00
- Customs duty 0 % €0.00
- Import VAT 19 % €190.00
- Total €1,190.00
Documents and checks for Switzerland
An estimate only. The customs value is the price including transport and insurance to the EU border. Excise duties, other fees and producer-specific anti-dumping rates are not included. Preferential rates need valid proof of origin. Country groups and exclusions: TARIC, as of November 2026.
Export measures for 3002590000
What applies when these goods leave the EU: export controls, dual-use and other authorisations, bans per destination and the supplementary unit of the export declaration.
| Destination | Start | Duty / Tax | Legal base Measure type | |
|---|---|---|---|---|
| IR | Iran, Islamic Republic of IR | 01-01-2022 | Document required banned without it | Restriction on export 476 |
1008 | All third countries 1008 | 15-11-2025 | Document required banned without it | Export authorization (Dual use) 478 |
 ZW | Zimbabwe ZW | 19-02-2026 | Document required banned without it | Export control 737 |
1008 | All third countries 1008 | 20-05-2023 | Document required banned without it | Export control - CITES 715 |
| BY | Belarus BY | 20-07-2025 | Document required banned without it | Export control 737 |
| RU | Russian Federation RU | 20-07-2025 | Document required banned without it | Import/export restriction - Common Military List (CML) goods 738 |
| RU | Russian Federation RU | 24-06-2023 | Document required banned without it | Export control 767 |
| BY | Belarus BY | 25-02-2025 | Document required banned without it | Export control 767 |
 CD | Congo, Democratic Republic of CD | 28-10-2026 | Document required banned without it | Export control 737 |
History
Duty rates and measures for this code over time (yearly snapshots).
Preferential rules of origin for 3002590000
What the goods must meet to count as originating in a partner country and get the preferential duty, per agreement.
EU-Egypt Association Agreement · Egypt
EU-Lebanon Association Agreement · Lebanon
EU-Morocco Association Agreement · Morocco
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:
– Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– Other
– – Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
Generalised Scheme of Preferences (GSP, GSP+, EBA) · Armenia, India, Kenya, Pakistan, Samoa, Solomon Islands, Syria, Vietnam
EU-Singapore FTA · Singapore
Pharmaceutical products / or: Manufacture from materials of any heading
Autonomous Trade Preferences (Western Balkans) · Kosovo
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:
- Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- Other:
- - Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- - Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- - Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- - Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- - Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EU-Canada CETA · Canada
A change from within any one of these subheadings or any other subheading.
EU-Chile Association Agreement · Chile
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: — Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — Other — — Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EU-Colombia/Peru/Ecuador Trade Agreement · Colombia, Ecuador, Peru
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:
Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Other:
Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
EU-Algeria Association Agreement · Algeria
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of microorganisms (excluding yeasts) and similar products:
– Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– Other
– – Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EPA CARIFORUM
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: – Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – Other: – – human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
EU Market Access Regulation (EPA) · Cameroon, Côte d’Ivoire, Ghana, Kenya
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:
– Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packing's for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– Other:
– – human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– – animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– – blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– – haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– – other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
EU-Jordan Association Agreement · Jordan
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: - Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - Other - - Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EU-Japan EPA · Japan
CTSH; A chemical reaction, purification, mixing and blending, production of standard materials, a change in particle size, isomer separation or biotechnological processing is undergone; MaxNOM 50 % (EXW); or RVC 55 % (FOB).
EU-Korea FTA · South Korea
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products. / or: Manufacture from materials of any heading
EU-Central America Association Agreement
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products,whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products / or: Manufacture from materials of any heading
EU-Mexico Global Agreement · Mexico
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: — Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — Other: — — Human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
EU-Palestine Interim Association Agreement · Palestine
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: - Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product - Other: -- human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product
EU-Tunisia Association Agreement · Tunisia
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EU-Viet Nam FTA · Vietnam
Pharmaceutical products. / or: Manufacture from materials of any heading.
Source: European Commission, Access2Markets (CC BY 4.0, shortened). The text of the agreement prevails. Access2Markets
Legal and explanatory notes for 3002590000
Notes to chapter 30
Notes 1. This chapter does not cover: (a) foods or beverages (such as dietetic, diabetic or fortified foods, food supplements, tonic beverages and mineral waters), other than nutritional preparations for intravenous administration (Section IV); (b) products, such as tablets, chewing gum or patches (transdermal systems), containing nicotine and intended to assist tobacco use cessation (heading 2404); (c) plasters specially calcined or finely ground for use in dentistry (heading 2520); (d) aqueous distillates or aqueous solutions of essential oils, suitable for medicinal uses (heading 3301); (e) preparations of headings 3303 to 3307, even if they have therapeutic or prophylactic properties; (f) soap or other products of heading 3401 containing added medicaments; (g) preparations with a basis of plaster for use in dentistry (heading 3407); (h) blood albumin not prepared for therapeutic or prophylactic uses (heading 3502); or (ij) diagnostic reagents of heading 3822. 2. For the purposes of heading 3002, the expression ‘immunological products’ applies to peptides and proteins (other than goods of heading 2937) which are directly involved in the regulation of immunological processes, such as monoclonal antibodies (MAB), antibody fragments, antibody conjugates and antibody fragment conjugates, interleukins, interferons (IFN), chemokines and certain tumour-necrosis factors (TNF), growth factors (GF), hematopoietins and colony-stimulating factors (CSF). 3. For the purposes of headings 3003 and 3004 and of note 4(d) to this chapter, the following are to be treated: (a) as unmixed products: (1) unmixed products dissolved in water; (2) all goods of Chapter 28 or 29; and (3) simple vegetable extracts of heading 1302, merely standardised or dissolved in any solvent; (b) as products which have been mixed: (1) colloidal solutions and suspensions (other than colloidal sulphur); (2) vegetable extracts obtained by the treatment of mixtures of vegetable materials; and (3) salts and concentrates obtained by evaporating natural mineral waters. 4. Heading 3006 applies only to the following, which are to be classified in that heading and in no other heading of the nomenclature: (a) sterile surgical catgut, similar sterile suture materials (including sterile absorbable surgical or dental yarns) and sterile tissue adhesives for surgical wound closure; (b) sterile laminaria and sterile laminaria tents; (c) sterile absorbable surgical or dental haemostatics; sterile surgical or dental adhesion barriers, whether or not absorbable; (d) opacifying preparations for X-ray examinations and diagnostic reagents designed to be administered to the patient, being unmixed products put up in measured doses or products consisting of two or more ingredients which have been mixed together for such uses; (e) placebos and blinded (or double-blinded) clinical trial kits for use in recognised clinical trials, put up in measured doses, even if they might contain active medicaments; (f) dental cements and other dental fillings; bone reconstruction cements; (g) first-aid boxes and kits; (h) chemical contraceptive preparations based on hormones, on other products of heading 2937 or on spermicides; (ij) gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments; (k) waste pharmaceuticals, that is, pharmaceutical products which are unfit for their original intended purpose due to, for example, expiry of shelf life; and (l) appliances identifiable for ostomy use, that is, colostomy, ileostomy and urostomy pouches cut to shape and their adhesive wafers or faceplates. Subheading notes 1. For the purposes of subheadings 3002 13 and 3002 14, the following are to be treated: (a) as unmixed products, pure products, whether or not containing impurities; (b) as products which have been mixed: (1) the products mentioned in (a) above dissolved in water or in other solvents; (2) the products mentioned in (a) and (b) (1) above with an added stabiliser necessary for their preservation or transport; and (3) The products mentioned in (a), (b) (1) and (b) (2) above with any other additive. 2. Subheadings 3003 60 and 3004 60 cover medicaments containing artemisinin (INN) for oral ingestion combined with other pharmaceutical active ingredients, or containing any of the following active principles, whether or not combined with other pharmaceutical active ingredients : amodiaquine (INN); artelinic acid or its salts; artenimol (INN); artemotil (INN); artemether (INN); artesunate (INN); chloroquine (INN); dihydroartemisinin (INN); lumefantrine (INN); mefloquine (INN); piperaquine (INN); pyrimethamine (INN) or sulfadoxine (INN). Additional note 1. Heading 3004 includes herbal medicinal preparations and preparations based on the following active substances: vitamins, minerals, essential amino-acids or fatty acids, in packings for retail sale. These preparations are classified in heading 3004 if they bear on the label, packaging or on the accompanying user directions the following statements of: (a) the specific diseases, ailments or their symptoms for which the product is to be used; (b) the concentration of active substance or substances contained therein; (c) dosage; and (d) mode of application. This heading includes homeopathic medicinal preparations when they meet the conditions of (a), (c) and (d) mentioned above. In the case of preparations based on vitamins, minerals, essential amino-acids or fatty acids, the level of one of these substances per recommended daily dose indicated on the label must be significantly higher than the recommended daily allowance to maintain general health or well-being.
Other explanatory notes for the chapter
Additional note 1 1. Herbal medicinal preparations are preparations based on one or more active substances, produced by subjecting a plant or parts thereof to a process such as drying, crushing, extraction or purification. Active substance means a chemically defined substance, a chemically defined group of substances (for example, alkaloids, polyphenols, anthocyanins) or a plant extract. These active substances must have medicinal properties for the prevention or the treatment of specific diseases, ailments or their symptoms. 2. Homeopathic medicinal preparations are prepared from products, substances or compositions called homeopathic stocks (mother tinctures). The degree of dilution must be indicated (for example, D6). 3. Vitamins or mineral preparations are preparations based on vitamins of heading 2936, on minerals including trace elements and mixtures thereof. They are used to treat or prevent specific diseases, ailments or their symptoms. Such preparations contain a much higher amount of vitamins or minerals, generally at least three times higher than the recommended daily allowance (RDA). As regards the recommended daily allowance (RDA) for certain vitamins and minerals, see, for example, the table in the Annex XIII to Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers (OJ L 304, 22.11.2011, p. 58) reproduced below: Vitamins and minerals | RDA Vitamin A | 800 μg Vitamin D | 5 μg Vitamin E | 12 mg Vitamin K | 75 μg Vitamin C | 80 mg Thiamin 1,1 mg Riboflavin | 1,4 mg Niacin 16 mg Vitamin B6 | 1,4 mg Folic acid | 200 μg Vitamin B12 | 2,5 μg Biotin 50 μg Pantothenic acid | 6 mg Potassium | 2 000 mg Chloride 800 mg Calcium 800 mg Phosphorus | 700 mg Magnesium | 375 mg Iron 14 mg Zinc 10 mg Copper 1 mg Manganese | 2 mg Fluoride 3,5 mg Selenium 55 μg Chromium 40 μg Molybdenum | 50 μg Iodine 150 μg 4. Recommended daily allowance (RDA) for adults with a weight of 70 kg, on essential amino acids, according to the joint WHO/FAO/UNU expert Consultation 2007: Essential Amino Acid | RDA (mg) Histidine | 700 Isoleucine | 1 400 Leucine 2 730 Lysine 2 100 Methionine + Cysteine | 1 050 Cysteine 287 Methionine | 728 Phenylalanine + Tyrosine | 1 750 Threonine | 1 050 Tryptophan | 280 Valine 1 820 Recommended daily allowance (RDA) for adults with a weight of 70 kg, on essential fatty acids, according to the joint WHO/FAO/UNU expert Consultation 2007. Types of essential fatty acids | Name of essential fatty acid | RDA (g) n-3 polyunsaturated fatty acids | linolenic acid (ALA) | 2 long-chain n-3 polyunsaturated fatty acids | EPA plus DHA | 0,25 n-6 polyunsaturated fatty acids | linoleic acid | 10
Sources: Combined Nomenclature 2026, Annex I to Regulation (EEC) No 2658/87 (CELEX 32025R1926), and the Explanatory Notes to the Combined Nomenclature (CELEX 02019XC0329(02)-20260213). The section and chapter notes are legally binding; the explanatory notes are guidance. EUR-Lex
Restrictions and flags for 300259
- Dual-use goods Regulation (EU) 2021/821, Annex I 30025900
Covers only part of the goods under this code (act names 30025900).
May be dual-use; check the Annex I entry 1C351 (correlation table is non-binding)
Read the act on EUR-Lex
For orientation only. Check the act before you rely on a flag; thresholds, derogations and exceptions are not shown in full. The dual-use table links codes to control list entries and is non-binding.
EU trade in 2025 for 300259
- Extra-EU imports
- €224.4M
- 164 t
- Extra-EU exports
- €218.4M
Top origin countries by import value
- Switzerland €135.1M
- United States €57.7M
- United Kingdom €25.2M
Brazil €1.8M
China €1.6M
CN8 codes below this code: 1. Source: Eurostat, Comext, CC BY 4.0, processed by hscode.info. Confidential trade is not allocated to codes.
Tariff changes for 300259 since 2016
- Jan 2022 3002590000 Code added
Month-by-month comparison of the European Commission’s TARIC extractions. Seasonal entry prices left out.
UK import duty for 300259
- 0%
Third-country duties of all UK commodity codes under this HS subheading. Source: UK Department for Business and Trade, as of Nov 2, 2026. The UK tariff differs from the EU tariff.
Import VAT in the EU
- Austria 20 %
- Belgium 21 %
- Bulgaria 20 %
- Croatia 25 %
- Cyprus 19 % maybe 5 %
- Czechia 21 % maybe 12 %
- Denmark 25 %
- Estonia 24 % maybe 9 %
- Finland 25.5 %
- France 20 %
- Germany 19 %
- Greece 24 % maybe 6 %, 13 %
- Hungary 27 %
- Ireland 23 %
- Italy 22 %
- Latvia 21 % maybe 12 %
- Lithuania 21 % maybe 5 %
- Luxembourg 17 %
- Malta 18 % maybe 5 %
- Netherlands 21 %
- Poland 23 %
- Portugal 23 %
- Romania 21 % maybe 11 %
- Slovakia 23 % maybe 5 %
- Slovenia 22 % maybe 9.5 %
- Spain 21 %
- Sweden 25 %
Standard rate per member state, on the customs value, the duty and transport to the destination. Reduced rates often depend on the use or the buyer and apply only where the country provides them for these goods. Source: European Commission, Taxes in Europe Database, as of Nov 2, 2026.
Rules of origin
Preferential rules of origin for subheading 300259 depend on the trade agreement. The Commission publishes them in Access2Markets.
Rules of origin on Access2MarketsInformation
When importing or exporting "Other", it is crucial to have the correct HS code or TARIC code. The HS code 3002590000 80 serves as the standard code for this product, ensuring that the appropriate duties and taxes are applied when crossing international borders.
To ensure your business transactions run smoothly when importing or exporting "Other", consider the following points:
- Inform yourself about the specific import and export regulations in the countries involved. This includes possible restrictions, taxes, and duties applicable to "Other".
- Check if any additional licenses, permits, or certificates are required to import "Other" into the destination country or export it from the country of origin.
- Make sure your trading partners have valid identification numbers, such as EORI numbers (Economic Operators Registration and Identification) in the EU, to streamline trade and minimize delays.
- Ensure that all trade- and customs-related documents (such as commercial invoices, packing lists, certificates of origin, and insurance policies) are accurately completed and adhere to the respective national regulations.
- Keep an eye on the current exchange rates, as well as packaging, shipping, and insurance costs, to accurately calculate trade costs.
In summary, the HS code or TARIC code for "Other" is 3002590000 80. Make sure you accurately use this code in all your trade and customs documents to guarantee smooth and hassle-free transactions. With these tips, you'll be better prepared for the challenges of international trade and can successfully import and export "Other".
HS Code structure
1. Chapter
There are 21 different sections, which are divided into 96 chapters. Exceptional chapters include chapter 77, which is reserved for future use, chapters 98 and 99, which are limited at national level, and chapter 99, which is a specific code for temporary changes. In the example above, chapter 30 was selected for pharmaceutical products
2. Heading
The heading determines the specific category within a certain chapter. In the example above, the 02 refers to Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified.
3. Subheading
The last two digits of the international harmonized code are more specific and define subcategories of products. In the example above, the 59 refers to Other.
HS Code tree structure
3000000000 80
Chapter PHARMACEUTICAL PRODUCTS
3002000000 80
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified
3002120000 10
- Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes
3002120000 80
- - Antisera and other blood fractions
3002130000 80
- - Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale
3002140000 80
- - Immunological products, mixed, not put up in measured doses or in forms or packings for retail sale
3002150000 80
- - Immunological products, put up in measured doses or in forms or packings for retail sale
3002410000 10
- Vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products
3002410000 80
- - Vaccines for human medicine
3002411000 80
- - - Vaccines against SARS-related coronaviruses (SARS-CoV species)
3002419000 80
- - - Other
3002420000 80
- - Vaccines for veterinary medicine
3002490000 80
- - Other
3002490010 10
- - - Cultures of micro-organisms
3002490010 80
- - - - Pathogens and cultures of pathogens
3002490020 80
- - - - Other
3002490081 10
- - - Other
3002490081 80
- - - - Pathogens and cultures of pathogens
3002490089 80
- - - - Other
3002510000 10
- Cell cultures, whether or not modified
3002510000 80
- - Cell therapy products
3002590000 80
- - Other
3002900000 80
- Other
3002901000 80
- - Human blood
3002903000 80
- - Animal blood prepared for therapeutic, prophylactic or diagnostic uses